AURORANCT06602479
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
At risk: Primary completion moved at least 45 days later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 8 more changesShow less
- Eligibility criteria expanded, about 29 words
- Enrollment closed, study ongoing
- Primary completion pushed from Dec 18, 2026 to Feb 2027
- Trial sites expanded: 54 → 71 locations
- Final enrollment: 309 participants (planned 488)
- Study completion moved earlier from May 7, 2027 to Feb 2027
- Secondary endpoints: details revised at 6 of 6 entries
- Study description expanded, about 5 words
- Minor Site details revised at 20 of 54 sitesv12
Notable Eligibility criteria expanded, about 63 wordsv11 Show 5 more changesShow less
- Enrollment target: 408 to 488
- Study sites: 60 to 54
- Secondary endpoints: 3 to 6
- Study description expanded, about 7 words
- Collaborators shortened, about 1 word
Notable Trial status: Active, Not Recruiting to Recruitingv10 Show 4 more changesShow less
- Enrollment target: 12 to 408
- Primary completion date: Sep 15, 2025 to Dec 18, 2026
- Study sites: 54 to 60
- Study completion date: Sep 15, 2025 to May 7, 2027
- Notable Lead sponsor: AstraZeneca to AbbVie
- Collaborators expanded, about 1 word
Show 7 earlier versionsHide 7 earlier versions
- Minor Study sites: 55 to 54v8
- Notable Enrollment target: estimated 408 to confirmed 12
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 61 to 55
- Primary and study completion dates: Sep 7, 2026 to Sep 15, 2025
- Minor Study sites: 60 to 61v6
- Minor Site details revised at 13 of 60 sitesv5
- Minor Study sites: 59 to 60v4
- Minor Site details revised at 8 of 59 sitesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Sep 2, 2026 to Sep 7, 2026
- Start date changed from estimate of Oct 2, 2024 to Oct 7, 2024
- Site details revised at 59 of 59 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
In the aCGRP-N cohort, 128 participants will be randomised on a 1:1 basis to receive MEDI0618 Dose A or placebo. After 104 participants total have been randomised, 3 other dose arms with MEDI0618 will be initiated and include 24 participants each.
In the aCGRP-N cohort, 128 participants will be randomised on a 1:1 basis to receive MEDI0618 Dose A or placebo. After 104 participants total have been randomised, 3 other dose arms with MEDI0618 will be initiated and include 24 participants each.
After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.
After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.
After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.
In the aCGRP-IR cohort there will be 1:1 randomisation of participants (50 to MEDI0618 and 50 to placebo).
In the aCGRP-IR cohort there will be 1:1 randomisation of participants (50 to MEDI0618 and 50 to placebo).
Drugs: MEDI0618, Placebo
Sites
71 sites in 8 countries
United States 34, Poland 10, Czechia 8, Spain 6, Germany 5, Italy 4, Hungary 3, Denmark 1